1Kivipelto M, Helkala EL, Laakso MP, et al . Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study[J]. BMJ,2001,322:1447-1451.
2Wellington CL. Cholesterol at the crossroads: Alzheimer' s disease and lipid metabolism[J] .Clin Genet,2004,66:1-16.
3Marlow L, Cain M, Pappolla MA, et al. Beta-secretase processing of the Alzheimer' s amyloid protein precursor (APP)[ J ]. J Mol Neurosci, 2003,20: 233 -239.
4Frears ER, Stephens DJ, Waiters CE, et al. The role of cholesterol in the biosynthesis of beta-amyloid [ J]. Neuroreport, 1999, 10: 1699-1705.
5Chauhan NB. Membrane dynamics, cholesterol homeostasis, and Alzheimer' s disease[J] .J Lipid Res,2003,44:2019-2029.
6Ehehalt R,Keller P,Haass C, et al. Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts[J] .J Cell Biol,.2003,160:113-123.
7Howland DS, Trusko SP, Savage MJ, et al. Modulation of secreted beta-amyloid precursor protein and amyloid beta-peptide in brain by cholesterol[J] .J Biol Chem, 1998,273:16576-16582.
8Refolo LM,Malester B,LaFrancois J, et al. Hypercholesterolemia accelerates the Alzheimer' s amyloid pathology in a transgenic mouse model[J]. Neurobiol Dis,2000,7:321-331.
9Wolozin B, Kellman W, Ruosseau P, et al. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors[J]. Arch Neurol,2000,57 : 1439-1443.
10Simons M,Schwarzler F, Lutjohann D, et al. Treatment with simvastatin in normocholesterolemic patients with Alzheimer's disease: a 26-week randomized, placebo-controlled, double-blind trial[ J ]. Ann Neurol,2002,52: 346-350.
